Real-world Study on the Effectiveness and Safety of Control-IQ Technology in Teenagers With Type 1 Diabetes Engaging in Regular Physical Activity

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

June 1, 2026

Conditions
Type 1 Diabetes Mellitus
Interventions
DEVICE

Tandem t:slim X2 with Control-IQ technology

Control-IQ is one of the second-generation AID technologies currently available worldwide and is approved for people \> 6 years. Control-IQ can predict glucose levels 30 minutes in advance and automatically adjust basal insulin delivery, providing corrective boluses if needed. The system can prevent hypoglycemia by suspending insulin delivery if glucose is predicted to drop below 70 mg/dl (8). Additionally, the device offers specific settings for circumstances such as sleep or exercise. When the exercise mode is activated, the system temporarily raises the minimum glucose target from 112.5 to 140 mg/dl to minimize the risk of hypoglycemia, a common effect of physical activity.

Trial Locations (1)

98125

RECRUITING

University Hospital of Messina, Messina

All Listed Sponsors
collaborator

University of Messina

OTHER

collaborator

University of Verona, Italy

UNKNOWN

lead

Bruno Bombaci

OTHER